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tion).1 Differences in the extent of thrombus resolu-
tion leave a variable degree of vein damage, which
results in ambulatory venous hypertension. Valves
The long-term complications of deep venous
thrombosis are caused by a combination of valvular
reflux and reduced venous outflow (relative obstruc-
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Objective: Resolution of venous thrombi is accompanied by an ingrowth of capillaries,
which appears to be analogous to angiogenesis in other tissues. Vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF) are major regulators
of angiogenesis. The aim of this study was to determine the temporal changes and the
location of VEGF and bFGF expression in a rat model of venous thrombus resolution.
Design and Methods: Thrombi were induced in the inferior venae cavae of rats by creat-
ing a stenosis to reduce blood flow by 80% to 90%. Thrombi, adjacent inferior vena cava
wall, and systemic blood were collected at 1, 3, 7, 14, 21, and 28 days after thrombus
generation (n = 9). Sham operations were performed (n = 5), and blood was collected
at 1, 3, and 7 days. VEGF and bFGF were measured with specific immunoassays, and
levels in tissues were expressed as picogram per milligram soluble protein. Tissues from
two animals that were humanely killed 7 days after thrombus formation were prepared
for histological examination. Immunohistochemistry was performed by the use of anti-
bodies against VEGF, bFGF, and ED-1 (a monocyte/macrophage marker).
Results: Laminated thrombi were reliably produced with a median weight at 1 day of 39
mg (range, 23-63 mg). There was a significant increase in thrombus VEGF concentra-
tion between 1 day (median, 247; range, 0-514) and 7 days (median, 556; range, 254-
1741) (P = .02). There was no difference between the seventh day and subsequent days.
There was a positive linear correlation between thrombus bFGF concentration and time
(R = 0.74, P < .0001), with a more than 300-fold increase in bFGF concentration over
the 28 days of the study. VEGF and bFGF concentrations in the adjacent vena caval wall
did not change significantly with time. The serum VEGF was significantly raised at 1
day (median, 5520 pg/mL; range, 4040-7912 pg/mL) and 3 days (median, 3880
pg/mL; range, 2564-7232 pg/mL) compared with 7 days (median, 1790 pg/mL;
range, 232-3228 pg/mL) (P < .0001). Similar changes in the serum VEGF also devel-
oped in the sham-operated animals. The serum bFGF (day 1 median, 15.5 pg/mL;
range, 1-42 pg/mL) did not change with time. Immunohistochemistry showed that the
VEGF antigen was localized to monocytes, endothelial cells, and spindle-shaped cells
within the thrombus. The bFGF antigen was localized to mononuclear cells and spindle-
shaped cells and was also present in the extracellular matrix.
Conclusion: VEGF and bFGF are found in organizing thrombi and have characteristic
temporal expression patterns, which suggest that they have a role in thrombus resolu-
tion. Augmenting angiogenic growth factor expression may enhance thrombus recanal-
ization, thus reducing long-term complications. (J Vasc Surg 2000;32:988-96.)
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are often damaged immediately,2 and in addition,
restricted outflow may cause valvular incompetence
even at sites at a distance from the thrombus.3
The process of thrombus resolution was observed
by Virchow4 and subsequently studied in more detail
by Cox5 and Sevitt.6 Thrombus is organized by a cel-
lular infiltrate and ingrowth of capillaries (angiogen-
esis) in a manner similar to wound healing.7 The
complex process of angiogenesis involves the interac-
tion of various cells, including monocytes, which
secrete a spectrum of angiogenic and antiangiogenic
growth factors.8 The mechanisms responsible for
thrombus resolution are now beginning to be inves-
tigated. Recent studies have shown that thrombus
organization can be stimulated by the chemokines
monocyte chemotactic protein-1 (MCP-1)9 and
interleukin-8,7 both of which have angiogenic activ-
ity. Enhancing thrombus recanalization with specific
angiogenic growth factors could result in more effec-
tive resolution, which would reduce the complica-
tions of post-thrombotic leg.
Vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (bFGF) are major reg-
ulators of angiogenesis and are increased in wound
healing, ischemic revascularization, and tumor
growth. We hypothesize that they may also mediate
thrombus recanalization. In this study we have
attempted to define the molecular mechanism that
controls thrombus organization by investigating the
expression VEGF and bFGF during thrombus reso-
lution in our animal model. 
METHODS 
Animal model of thrombus resolution. The res-
olution of venous thrombi was studied with a previ-
ously described rat model of inferior vena caval
thrombosis.10 Adult male Wistar rats were anes-
thetized with halothane and buprenorphine, and
laparotomy was performed. The inferior vena cava was
exposed below the renal veins, and flow was measured
with an ultrasonic flow probe (Linon Instrumentation,
Diss, UK). A 4-0 silk ligature was then placed around
the cava and progressively tightened until flow was
reduced by 80% to 90% of the original flow. The liga-
ture was left in place, the wound was closed, and the
animal recovered. The study was performed under the
Animals (Scientific Procedures) Act 1986.
Collection and processing of tissue samples.
Thrombi were induced in six cohorts of nine animals.
The inferior vena cava and the contained thrombus
were harvested from the confluence of the iliac veins up
to the renal veins at time intervals of 1, 3, 7, 14, 21, and
28 days after thrombus formation. Blood was collected
by direct cardiac puncture into vials that contained
serum separation gel and clot activator (Vacutainer).
Tissues samples were separated, weighed, and snap
frozen at –80°C. Tissues were then cryohomogenized
in liquid nitrogen by means of a Mikro-Dismembrator
II (B. Braun Biotech International, Melsungen,
Germany) and resuspended in Dulbecco’s phosphate-
buffered saline (Sigma, UK). Homogenates were spun
at 14,000g for 5 minutes at room temperature. The
supernatants were decanted, snap frozen, and stored
at –80°C before assay. Serum was separated from the
collected blood by centrifugation at 3000g for 10
minutes at room temperature, snap frozen, and stored
at –80°C before assay.
In addition, three cohorts of five animals
underwent sham operations. The procedure was
identical in all respects, including the placement of
a ligature around the cava, but the ligature was
tied loosely so as not to constrict the caval blood
flow. Blood was collected from these animals at 1,
3, and 7 days after operation.
VEGF and bFGF assay. VEGF and bFGF were
measured in tissue homogenates and serum samples
with a human VEGF competitive enzyme immunoas-
say (Accucyte; Cytimmune, College Park, Md) and 
a human bFGF sandwich enzyme immunoassay
(Quantikine HS; R+D Systems, Abingdon, UK). Both
assays cross-react with the rat antigens. Thrombus
protein concentration was measured by means of the
Coomassie colorimetric method with a bovine serum
albumin standard (Pierce, Rockford, Ill).
Immunohistochemical studies. Thrombi were
formed in two animals and harvested after 7 days.
Tissues were fixed in 10% formal saline and embed-
ded in paraffin wax. Sections of 5 µm were taken at
0.5-mm intervals through each thrombus and
stained by the use of a monoclonal antibody against
VEGF and a polyclonal antibody against bFGF
(Santa Cruz Biotechnology, Inc, Santa Cruz, Calif).
Sections were also stained with a monoclonal anti-
body against rat monocytes (ED-1; Serotec, Oxford,
UK). Primary antibody binding was localized with a
biotinylated second antibody in conjunction with a
streptavidin-peroxidase complex. Sections were
counterstained with Nuclear Fast Red (Vector
Laboratories, Peterborough, UK).
Statistical analysis was performed with the Mann-
Whitney test for nonparametric data. All tissue results
are expressed as picogram per milligram soluble protein.
RESULTS
Thrombi were initially occlusive with a median
weight at 1 day of 39 mg (range, 23-63 mg). By 4
JOURNAL OF VASCULAR SURGERY
990 Waltham et al November 2000
weeks the thrombi had resolved to a remnant in the
vein wall.
Thrombus VEGF. There was a significant increase
in thrombus VEGF concentration in the thrombus
between 1 day (median, 247; range, 0-514) and 7 days
(median, 556; range, 254-1741) (U = 11.0, P = .02)
(Fig 1). After 7 days there was considerable variation in
VEGF concentration (range, 0-7726), although it was
always significantly higher than the first day (P < .05).
There was no significant difference between the sev-
enth day and all subsequent days. Three of the thrombi
that had VEGF levels greater than three SDs of the
mean appeared more organized and smaller.
Thrombus bFGF.  There was a positive correla-
tion between thrombus bFGF concentration and
time (R = 0.74, P < .0001) (Fig 2). There was a
greater than 300-fold increase in bFGF concentra-
tion from the first day (median, 1.1; range, 0.38-
5.37) to 28 days (median, 349; range, 198-1059).
Inferior vena cava VEGF and bFGF. VEGF
concentration (median, 159; range, 0-831) and
bFGF concentration (median, 311; range, 116-884)
in the adjacent inferior vena cava did not change
with time (Figs 3 and 4).
Serum VEGF. Serum VEGF was significantly
raised at 1 day (median, 5520 pg/mL; range, 4040-
Fig 1. Thrombus VEGF content during resolution. Horizontal line represents median value. There
was significant increase in thrombus concentration of VEGF from 7 days and thereafter compared with
first day. †P < .05 (Mann-Whitney test).
Fig 2. Thrombus bFGF content during resolution. Horizontal line represents median value. There was
positive correlation between thrombus bFGF concentration and time (R = 0.74, P < .0001).
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7912 pg/mL) and 3 days (median, 3880 pg/mL;
range, 2564-7232 pg/mL) compared with 7 days
(median, 1790 pg/mL, range 232-3228 pg/mL)
(both P < .0001) (Fig 5). There was no change after
7 days. The sham-operated animals had the same
high levels at 1 and 3 days. There was no difference
between VEGF levels in the experimental and sham
animals at days 1, 3, and 7.
Serum bFGF. Serum bFGF did not change with
time (median, 15 pg/mL; range, 1-46 pg/mL) (Fig 6).
There was no difference to sham-operated serum bFGF.
Histology. VEGF expression was localized to
the periphery of the thrombus at 7 days (Fig 7).
High-power microscopy (Fig 8, A) and comparison
with ED-1–stained sections (Fig 8, B) demonstrated
that VEGF was localized to endothelial cells, mono-
cytes, and spindle-shaped cells in the thrombus.
Cells with endothelial morphology staining for
VEGF appeared to be forming tubular structures
near the edge of the thrombus (Fig 7). The bFGF
was expressed by mononuclear cells and spindle-
shaped cells in the thrombus and was also present in
the extracellular matrix (Fig 9). Immunoglobulin G
controls showed no staining.
DISCUSSION
In this study both VEGF and bFGF were found
in resolving thrombi and had distinctive temporal
Fig 3. VEGF content in adjacent inferior vena cava during thrombus resolution. Horizontal line rep-
resents median value. There was no change in VEGF concentration with time.
Fig 4. bFGF content in adjacent inferior vena cava during thrombus resolution. Horizontal line rep-
resents median value. There was no change in bFGF concentration with time.
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patterns of expression. This expression of angiogenic
growth factors within a resolving thrombus is a
novel finding. There was a rise in VEGF concentra-
tion in the thrombus, which appeared to peak at
about 14 to 21 days, and there was a strong linear
correlation between bFGF concentration in the
thrombus and time. No change was found in the lev-
els of either angiogenic growth factor in the adjacent
vein wall. The initial rise in VEGF serum concentra-
tion after thrombus formation was also found in
sham animals and was presumably related to surgical
dissection and postoperative wound healing. A rise
in serum VEGF as a consequence of thrombus reso-
lution might have been overwhelmed by the increase
in its concentration after surgery. VEGF expression
was histologically localized to several cells in the
thrombus, including endothelial cells and the mono-
cyte infiltrate. Some of the cells expressing VEGF
Fig 5. Serum VEGF. There was significant increase in serum VEGF concentration at days 1 and 3
compared with day 7. This was also seen in sham-operated animals. †Values compared with day 7, P
< .0001 (Mann-Whitney test).
Fig 6. Serum bFGF. There was no change in serum bFGF with time and no difference between ani-
mals with thrombus and sham-operated animals.
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appeared to be forming lumens and were possibly
migrating endothelial cells beginning to recanalize
the thrombus. Expression of bFGF was found on
mononuclear cells and spindle-shaped cells within
the thrombus.
In this study we have demonstrated expression of
angiogenic proteins in resolving thrombi, but we
have not confirmed synthesis of these proteins by
any specific cells. It is possible that the angiogenic
factors found are synthesized elsewhere and
sequestered into the thrombus. Both VEGF and
bFGF are synthesized by many cell types, including
monocytes, fibroblasts, and endothelial cells.11 The
strong localization of the proteins to these latter
three cell types suggests that production within the
thrombus is more likely. We are currently attempting
to confirm synthesis of angiogenic growth factors
within resolving thrombi using in situ hybridization
and reverse transcription polymerase chain reaction.
The process of thrombus generation and resolu-
tion in rats is not totally comparable to humans, but
this type of study could not be ethically performed
in humans. In our model, thrombus is formed in
flowing blood, and it is therefore superior to models
involving simple venous occlusions that produce a
“clot” rather than thrombus. It also has the poten-
tial advantages that endothelium is maintained and
the hemostatic balance is unchanged. Laminated
thrombi formed in this model closely resemble
human venous thrombi.
Recanalization with new vascular channels occurs
within all organizing thrombi that we have examined,
partly as a consequence of thrombus contraction and
partly as a result of endothelial cell proliferation,
endothelial cell migration, and new vessel formation.
The vascular spaces formed within the thrombus
have been shown to communicate with both the ves-
sel lumen4 and the vasa vasorum.12 Thrombus
recanalization is therefore similar to angiogenesis,
and the same mechanisms that regulate new vessel
formation elsewhere may affect the process of throm-
bus resolution. The origin of the endothelial cells
that are found within new channels in the thrombus
is unknown. They may be derived from proliferation
of local venous endothelial cells or circulating
endothelial progenitor cells. Alternatively, it has been
suggested that monocytes or other cells may be able
to change their phenotype into endothelial cells.13
Angiogenesis in wound healing is orchestrated
by monocytes, and these cells may also have an
important role in thrombus organization and reso-
lution.14 They infiltrate the thrombus where they
produce and release tissue plasminogen activator
Fig 7. Thrombus 1 week after formation (original magni-
fication ×100) stained for VEGF (black). T, Thrombus; V,
vein wall; →, cells with endothelial morphology appearing
to form tubules near periphery of thrombus and lining
retraction spaces between thrombus and vein wall.
Fig 8. A, High-power micrograph (original magnification
×400) of thrombus edge (T) and vein wall (V) stained for
VEGF (black). VEGF is localized to mononuclear cells
(m), spindle-shaped cells (s), and endothelium (e). B,
High-power micrograph (original magnification ×400) of
thrombus edge (T) and vein wall (V) stained for monocyte
marker ED-1.
A
B
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and urokinase.15 They can also actively degrade fi-
brin in the absence of plasmin16 and produce
inhibitors of fibrinolytic activity. Monocytes are
capable of synthesizing and secreting a number of
proteolytic and angiogenic factors that direct tissue
remodeling.17 Little, however, is known of the
mechanisms by which monocytes are recruited into
the thrombus or how they are activated, but modu-
lation of these processes may have a profound effect
on thrombus resolution. Damaged endothelial cells
or platelets within the thrombus may release many
cytokines and growth factors that influence mono-
cyte migration and function. We have already shown
that levels of the cytokine MCP-1 are raised during
thrombus resolution, and when this cytokine is
directly injected into venous thrombus, it alters
organization.9 Part of the effect produced by inject-
ing MCP-1 may have been as a consequence of its
angiogenic properties. 
Most patients with a deep vein thrombosis even-
tually have long-term complications of pain,
swelling, lipodermatosclerosis, and ulceration,18
which have a large social and economic impact.
These symptoms are caused by a combination of
valvular incompetence and persistent outflow restric-
tion. Thrombus may damage the valves by direct
involvement and may also produce valvular incom-
petence in the distal venous system.3 Current treat-
ment with anticoagulants has little, if any, effect on
thrombus resolution19 and does not preserve valves.
Early natural recanalization20 and rapid pharmaco-
logic thrombolysis21 preserve valve integrity and
may improve clinical outcome.22,23 Many, however,
believe that the risk of hemorrhagic complications
may not justify the use of thrombolytic agents,24 and
better treatments are needed for patients who pre-
sent at a late stage. 
Treatment of ischemic heart disease and peripheral
vascular disease with angiogenic growth factors has
produced promising results.25 Similar treatments
could be used to produce rapid resolution of venous
thrombosis. Promoting thrombus recanalization with
angiogenic growth factors might improve venous out-
flow and preserve valvular competence. Wakefield et al
have already shown that the use of interleukin-8, a
CXC chemokine and potent inducer of angiogenesis,
can promote the migration of inflammatory cells into
a thrombus and enhance early neovascularization.
VEGF and bFGF are well-recognized angiogenic
growth factors and have a synergistic action.26 VEGF
is a potent and specific endothelial mitogen and
chemotactic factor, whereas bFGF also has significant
angiogenic activity.27 Angiogenic growth factors may
have a local action within the thrombus, but in addi-
tion, VEGF mobilizes endothelial progenitor cells
from the bone marrow that circulate and contribute to
the formation of new channels in different circum-
stances.28 These cells may not only help to recanalize
the thrombus but may also encourage collateral devel-
opment. We are now undertaking further studies to
determine whether thrombus recanalization or venous
collateral development can be modified by augment-
ing the expression of angiogenic factors.
We thank The Special Trustees of St Thomas’ Hospital
for funding this study.
Fig 9. A, Thrombus 1 week after formation (original magnification ×200) stained for bFGF (black).
T, Thrombus; V, vein wall. bFGF is localized to a variety of cell types including mononuclear cells,
spindle-shaped cells, and cells lining channels forming within the thrombus →. B, High-power micro-
graph (original magnification ×400) of thrombus stained for bFGF (black) showing mononuclear cells
expressing bFGF.
A B
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DISCUSSION
Dr Edmund J. Harris (Stanford, Calif). Dr Wakefield, Dr
Ehrenburg, members and guests. Mr Waltham comes to us
today with the promise of clarifying the relationship between
angiogenesis and thrombus recanalization in deep venous
thrombosis. The author’s group has extensive experience
with a rat model of deep venous thrombosis involving the
inferior vena cava. The group proposes to measure the
expression of VEGF and bFGF in this well-developed model
to help us gain insight into the role of these angiogenic fac-
tors and recanalization of venous thrombosis.
The group did not measure local expression of these
angiogenic proteins, but rather quantified protein levels
in the excised segments of inferior vena cava at serial
timepoints, and compared these protein levels with sham-
operated animals and serum protein levels acquired at sac-
rifice. Histological evaluation of specimens was per-
formed at 7 days post-thrombosis, with localization of the
protein performed by immunohistochemical analysis.
The group noticed a significant increase in VEGF in
the thrombus between 1 and 7 days, which was not
noticed in the sham-operated group. Yet both experimen-
tal and sham-operated groups showed significant elevation
in the serum VEGF at 1 and 3 days and less so by 7 days.
Is it possible that the thrombus is merely trapping VEGF
and the thrombus is not actively producing VEGF as the
authors suggest? I would be more comfortable with in situ
hybridization data localizing VEGF mRNA to the
endothelial cells, monocytes, and spindle-shaped cells
observed in the immunohistochemical localization of
VEGF protein. Do the authors have any in situ hybridiza-
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tion studies confirming the presence of increased VEGF
transcript in this model? 
Similarly, bFGF mRNA was not characterized in the
thrombus or the vessel wall. Protein levels of bFGF
increased over time, but the initial levels were significantly
lower than those in the adjacent vena cava. Even as the
thrombus levels of bFGF increased over time, these peak
levels do not appear significantly different than the bFGF
levels in the adjacent nonthrombosed vena cava, admit-
tedly, values that had a wide variability. Although serum
bFGF levels remain low throughout the study period in
both experimental and control animals, the thrombus
bFGF levels begin lower than adjacent vena caval levels
and then approach parity by 28 days when the thrombus
has resolved. This would suggest to me that thrombus
suppresses bFGF expression and bFGF is not involved in
thrombus recanalization. What are your thoughts on this
alternative interpretation of your data?
I too have an interest in the process of thrombus resolu-
tion in deep venous thrombosis, and my work has previously
been presented at the American Venous Forum. My rat
model is one of chronic iliac venous obstruction rather than
one of venous stenosis, as in this model. In my studies,
thrombus recanalization occurred by 4 weeks, even with
complete ligation of the iliac vein. The unexpected finding
was the development of neovascular channels around the
area of ligation, again suggesting angiogenesis as a mediator
of thrombus recanalization. Did you notice any extravascu-
lar channels in your model as well? Thrombin is a potent
stimulator for expression of angiogenic proteins, mediated
via its stimulation of proteinase-activated receptors found in
mesenchymal, smooth muscle, and endothelial cells. In our
model, the thrombin receptor is significantly upregulated
during thrombus resolution. Clot-bound thrombin being
released by the process of thrombolysis is the presumed stim-
ulus. Did you measure thrombin activity in the resolving
thrombus in your model? I would bet that thrombin levels
would correlate with the rise in the VEGF levels, both in
thrombus and in the adjacent vena cava, due to washout of
the released thrombin.
I enjoyed reading your clear manuscript and thank you
for your efforts to provide me the manuscript in a timely
manner. I thank the forum for the opportunity to discuss
this work.
Mr Matthew Waltham. I thank Dr Harris for his con-
structive comments.
In this study we have shown that the concentrations of
VEGF and bFGF in resolving thrombi increase with time
and that these factors are localized to cells within the
thrombus. It is not possible to say whether this is the result
of production within the thrombus or trapping by these
cells, but we did find that thrombus concentration of these
growth factors was independent of the inferior vena cava
concentration adjacent to the thrombus. We are now per-
forming both quantification of mRNA expression in the
thrombus RNA extracts and in situ hybridization analysis.
We have not specifically studied extravascular channels pro-
duced during recanalization in this model. The strengths of
our model are that true laminated thrombi are formed
within flowing blood and that recanalization is studied in a
nonoccluded vessel. This closely resembles the true clinical
scenario. Your observation, Dr Harris, of extravascular
channels is very interesting, and their development may
involve a mechanism related to that of collateral formation
elsewhere. Treatment of venous thrombosis with angio-
genic growth factors may also promote development of
such collaterals. We have not measured thrombin within
our model. The list of factors with angiogenic activities
seems to grow longer by the week, and we have decided to
look at two that may have therapeutic benefit. We particu-
larly picked VEGF and bFGF because they are the two best
characterized factors and are known to play a central role in
controlling angiogenesis in other tissues. Of course, the
true test of which factors are important in thrombus
recanalization and resolution is whether recanalization can
be enhanced or blocked by stimulating or inhibiting the
particular factor.
Thank you again for your comments and thank you to
the American Venous Forum for giving me the pleasure of
presenting this paper.
